🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT07047937
Enrolling by invitation Observational

Explainable Machine Learning for Predicting Early Gastric Cancer

NCT07047937 · tracked via the Priya Life Science China tracker
Sponsor
Wenzhou Central Hospital
Phase
Observational
Started
2025-06-28
Last updated
2025-07-02

Condition(s) studied

Early Gastric Cancer

Study summary

Abstract Background: Early detection of gastric cancer is crucial for improving patient survival rates. Currently, the primary method for diagnosing early-stage gastric cancer is endoscopy, which has various limitations. Additionally, single laboratory tests continue to fall short of the requirements for early screening. This study aims to develop a machine learning (ML) model using clinical data to predict early-stage gastric cancer and apply SHapley Additive exPlanation (SHAP) values to explain the ML model.

Methods: This study involved patients who provided gastric tissue samples at Wenzhou Central Hospital from 2019 to 2023. The investigators gathered various laboratory test results from these patients. The investigators constructed and evaluated nine ML models to predict early-stage gastric cancer, using the area under the curve (AUC), accuracy, and sensitivity to assess their performance. For the most effective prediction model, The investigators utilized the SHAP method to determine the features' importance and explain the ML model.

Eligibility

Sex
ALL
Min age
Max age
Healthy volunteers
No
Inclusion Criteria: * all patients with a gastric tissue pathology result are included Exclusion Criteria: * unclear or incomplete pathology results * significant missing laboratory data * progressive and advanced gastric cancer

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Wenzhou Central Hospital Wenzhou Zhejiang

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07047937 on ClinicalTrials.gov ↗ ← All trials in China